Author

K. Polyak

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Approach:statistical model· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Feit· 1 shared A. Helland· 1 shared A. Saetersdal· 1 shared A. Trinh· 1 shared A. V. LEE· 1 shared A.-L. Borresen-Dale· 1 shared C. Cai· 1 shared C. DSantos· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Feit

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer

Z. Li, F. Chen, L. Chen, J. Liu, D. Tseng, F. Hadi, S. Omarjee, K. Kishore, J. Kent, J. Kirkpatrick, C. DSantos, M. Lawson, J. Gertz, M. J. Sikora, D. J. McDonnell, , A. V. LEE

EstroGene2.0 is a multi-omic database that compiles data on estrogen receptor responses and resistance in breast cancer, revealing diverse transcriptomic changes and identifying key targets.

bioRxiv · Jun 28, 2024 · PreprintCancer Biology

A non-canonical EZH2 function sensitizes solid tumors to genotoxic stress

Y. LIAO, C.-H. Chen, N. Shah, T. Xiao, A. Feit, M. Yang, C. Cai, S. Gao, P. Xue, Z. Liu, H. Xu, J. Lee, W. Li, S. Mei, R. S. Pierre, , K. Xu

This study shows EZH2 inhibitors inhibit CRPC growth by downregulating DNA repair genes, making cancer cells more sensitive to genotoxic stress.

bioRxiv · Sep 11, 2020 · PreprintCancer Biology

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumors

I. H. Rye, A. Trinh, A. Saetersdal, D. Nebdal, O. C. Lingjaerde, V. Almendro, K. Polyak, A.-L. Borresen-Dale, A. Helland, F. Markowetz, H. G. Russnes

This study examines how intra-tumor heterogeneity in HER2 expression and copy number affects treatment outcomes in HER2+ breast cancer patients.

bioRxiv · Apr 18, 2018Cancer Biology